NCT06539195 - DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

March 13, 2024

Primary Completion Date

October 31, 2027

Study Completion Date

April 30, 2028

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG

DZD8586

Daily dose of DZD8586 at 25 mg

DRUG

DZD8586

Daily dose of DZD8586 at 50 mg

DRUG

DZD8586

Daily dose of DZD8586 at 75 mg

Trial Locations (16)

100083

RECRUITING

Research Site, Beijing

116021

NOT_YET_RECRUITING

Research Site, Dalian

210009

NOT_YET_RECRUITING

Research Site, Nanjing

230031

RECRUITING

Research Site, Hefei

250117

RECRUITING

Research Site, Jinan

276002

RECRUITING

Research Site, Linyi

300020

RECRUITING

National Clinical Research Center for Blood Diseases, Blood Disease Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin

300181

RECRUITING

Research Site, Tianjin

310009

RECRUITING

Research Site, Hangzhou

410031

RECRUITING

Research Site, Changsha

430023

RECRUITING

Research Site, Wuhan

450003

RECRUITING

Research Site, Zhengzhou

510060

RECRUITING

Research Site, Guangzhou

530016

RECRUITING

Research Site, Nanning

610041

RECRUITING

Research Site, Chengdu

710061

RECRUITING

Research Site, Xi’an